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Abstract: The inclusion of biofunctional molecules with synthetic bone graft substitutes has the
potential to enhance tissue regeneration during treatment of traumatic bone injuries. The clinical
use of growth factors has though been associated with complications, some serious. The use of
smaller, active peptides has the potential to overcome these problems and provide a cost-effective,
safe route for the manufacture of enhanced bone graft substitutes. This review considers the design
of peptide-enhanced bone graft substitutes, and how peptide selection and attachment method
determine clinical efficacy. It was determined that covalent attachment may reduce the known risks
associated with growth factor-loaded bone graft substitutes, providing a predictable tissue response
and greater clinical efficacy. Peptide choice was found to be critical, but even within recognised
families of biologically active peptides, the configurations that appeared to most closely mimic the
biological molecules involved in natural bone healing processes were most potent. It was concluded
that rational, evidence-based design of peptide-enhanced bone graft substitutes offers a pathway to
clinical maturity in this highly promising field.
Keywords: bone repair material; biomimetic peptides; surface functionalisation; tissue engineering
1. Introduction
With an ageing population, there is a growing need for improved bone tissue regen-
eration [1–3]. After injury, given the appropriate conditions, bone tissue has the capacity
to regenerate fully [4]. Healing, however, can be compromised by a number of factors
including defect size, underlying disease conditions and/or poor vascularisation, resulting
in a non-healing defect or fracture non-union which lacks the ability to complete self-repair
processes. The prevalence of non-union can range from 2.5 to 46%, depending on the
severity of the defect and age of the patient, and other local factors [5,6]. These clinical
challenges are accompanied by a reduced quality of life and therefore surgical interven-
tion is required to restore health and function. With the prevalence of non-union post
therapy currently at 10%, there is a growing demand for enhanced osteoconductive and
osteoinductive medical devices for bone tissue regeneration [7–9]. Osteoconduction is the
process of bone cells and tissues regenerating at the surface of a scaffold biomaterial such
as hydroxyapatite (HA), following implantation into established bony tissue; while osteoin-
duction is the biochemical stimulation of bone tissue regeneration through the recruitment
and directed differentiation of mesenchymal stem cells (MSCs), and is associated with
autografts and specific alloplastic grafts that have been modified with orthobiologic and
related agents [4,10–12]. While advances in the development of osteoinductive bone grafts
have improved the consistency of bone healing for many patients, they have also intro-
duced new clinical complications, and challenges remain among elderly or compromised
patients [13,14].
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Although autografts are considered osteoinductive and the “gold standard”, the
requirement for a second surgical site (with pain and a risk of infection or donor site
morbidity) means this is not an ideal solution. The medical research community is therefore
focused on further developing alloplastic graft substitutes through the incorporation of
molecules to promote bone healing, rendering them osteoinductive, thereby alleviating the
limitations and concerns surrounding other grafting materials [15]. The unmet clinical need
for alloplastic bone graft substitutes, which provide consistent and predictable healing
of bone defects led to the development and application of orthobiologics such as bone
morphogenetic protein (BMP) 2 and 7, in the form of adsorbed protein inclusions [12,15–18].
Two BMPs are currently FDA approved for clinical use: recombinant human (rh)
BMP-2 and rhBMP-7, with BMP-2 thought the most effective and included in a clinical
product: Infuse®, produced by Medtronic Inc.©, is a collagen sponge carrier for rhBMP-2,
for spinal fusion. However, the clinical outcomes related to the use of rhBMP-2 are disputed
in the literature. Successful bone regeneration through the use of rhBMP-2 is reported
in a plethora of multi-centre trails [19–21]. There is also a large amount of published
work claiming no significant enhancement of non-union rates, and even adverse events
associated with its use, many of which are summarised in a review written by Epstein in
2013 focused on complications in spine surgery related to Infuse® [4,10,15,16,22]. These
issues are believed to be the result of the high concentrations used, non-specific action
and uncontrolled ectopic effects when the BMP has travelled in large concentrations to
undesirable regions of the body. BMP-7 has also been incorporated into a medical product.
OP-1, produced by Stryker©, contains rhBMP-7, and again, the published literature is in
disagreement regarding its effectiveness. It has been shown that when used, in combination
with a hydrogel carrier and bovine collagen type 1, rhBMP-7 stimulates the healing of
non-unions at a rate similar to that of an autograft [23], while conversely, in another
article similar healing patterns were conveyed in sites treated and untreated with rhBMP-7,
indicating no significant differences [24]. The inability to predict or control tissue responses
to orthobiologic grafts is associated with excessive bone tissue regeneration which is
harmful to patients [4,10].
The use of smaller biomolecules, specifically small-chain peptides developed from
certain domains within larger biomolecules, offers a potential solution to the issues sur-
rounding larger biomolecule inclusions. Peptides are thought to allow for significantly
greater control over cellular interactions in terms of consistency and potency [25], and
it has also been suggested that there are specific advantages to covalent attachment of
these peptides over that of physical adsorption, including controllable concentrations and
directed peptide conformations, which will affect cellular interaction. A non-eluting device
would also allow for a reduced medical device classification, and is therefore of significant
clinical interest [26]. The use of peptides to improve bone tissue regeneration was reviewed
by Wang et al. [27], who also covered attachment methodologies and the general progress
in the area. The authors highlighted the need for much more work in the field, with the
need for systematic studies to more strongly elucidate the effects of specific peptides and
the preparation methods used for these modified alloplastic grafts.
Therefore, in this review, we propose an overview of the different strategies proposed
in the literature to design peptide-enhanced bone graft substitutes and a critical perspective
of the peptide selection and role of attachment methodology on their clinical efficacy.
Hence, the scientific community and researchers in the tissue engineering field can get
insights into the design and manufacture of bioactive graft materials able to efficiently
regenerate bone.
2. Peptides
Peptides, short amino acid chains that are generally copied from active sites in larger
protein molecules, offer an approach to overcome problems associated with orthobiologics
while retaining the osteogenic effects. They mimic the signalling and/or the binding
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domains of the larger proteins, which offers a potential solution to problems with steric
effects, immunogenicity and susceptibility to degradation.
Steric effects and folding problems represent a major issue. In response to interaction
with a material, bone proteins will fold in certain manners, determined by the specific
properties of the material [28]. This folding is highly specific, and therefore difficult to
control, manipulate and can often be random [25]. It can lead to the signalling and binding
domains of the large protein becoming sterically unavailable for cellular interaction [25].
To overcome this unavailability, high dosages are used, which are inherently difficult to
control and, as mentioned previously, often result in adverse effects [22]. In comparison,
bound peptides have a higher stability and undergo highly controllable determined folding,
making them available for cellular interaction, and therefore dosage control is significantly
less difficult. Peptides can alleviate the issues surrounding steric effects associated with
larger proteins, and even have an increased repeatable cellular signal [29].
Immunogenicity is also a problem, as producing proteins via recombinant human
expression carries a high economic cost, as they inherently carry the risk of immunogenicity,
which must be removed through expensive purification and quality controls [30]. The FDA
approved BMP modified bone grafts, as an average, cost approximately four times that
of their non-modified alloplastic bone graft alternatives [4]. Peptides can be fabricated
synthetically using liquid or solid-state phase synthesis, which offers no risk of immuno-
genicity and a significantly reduced cost through reduced material wastage, and processing
and purification times [25,30].
There are also potential issues in the long-term stability of proteins. Subtle changes in
pH and/or temperature during production, storage, implantation or within the human
body can cause the irreversible denature of proteins [31,32]. This sensitivity is related
to their functionality and structure (secondary, tertiary and quaternary folding) being
destabilised through the breakage of weak hydrogen bonding. Peptides are significantly
more resistant to pH and/or temperature changes as their function is not impaired unless
covalent bonds are broken [30]. Once again this allows peptides to alleviate another prob-
lem associated with large proteins, and their resistance opens up potential immobilisation
routes not available to proteins [29].
There are a vast array of proteins associated with bone and its regeneration. Due
to the quantity of different proteins and large number of possible cellular interactions
there are many specific peptides of interest. This number is increased further by the
possibility of combinations and variations based around a single peptide sequence. It is
therefore understandable that most interactions between peptides and cells are yet to be
fully understood. In 2016, there were detailed reviews published around utilising various
bioactive peptides for bone tissue regeneration, which provides evidence that there is
currently significant growing interest in this area. Of these reviews, the state of the art was
covered concisely by two groups: Pountos et al. [33] and Visser et al. [34]. With the number
of peptides, reported to enhance bone tissue regeneration, growing and compounded by
the various modifications of each peptide available, there is an increasing need to compare
peptides in terms of bioactive capability. The reviews published by Pountos et al. and
Visser et al. did not facilitate this important step.
To better understand current knowledge, a critical review of the numerous published
peptide investigations related to bone tissue regeneration was performed. Due to the large
number of variables concerning research of this nature (in vitro cell types used, number
of cells, in vivo studies, possible peptide immobilisation routes, cell behaviours measured
and base graft material to name a few), it is not possible to compare peptides quantitatively.
However, the studies can be categorized through both attachment methodology and
peptide grouping to allow for comparison.
3. Attachment Methodology
The attachment of peptide to substrate is important. Most of the proteins and pep-
tides currently being utilised for stimulating osteoinduction in allografts, xenografts or
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alloplastic bone graft substitutes are soluble. This solubility leads to an immediate dissipa-
tion upon implantation at the targeted delivery site, resulting in a reduced efficiency and
potency of the bioactive molecule on the targeted tissues [4]. These specific biomolecule
inclusions can be troublesome elsewhere in the body, often disturbing homeostasis. There
is evidence showing certain peptides can inhibit cell adhesion, hinder bone formation,
stimulate unwanted bone resorption and impair cell metabolic activity [32,35,36]. As such,
peptides are often conjugated to substrates in order to enhance, sustain and control the
desired effects.
A variety of methodologies are used for this purpose. These range from simple adsorp-
tion to more complex, multi-stage chemical processes. To prevent the rapid biodegradation
of the substrate, a large proportion of biomaterials used in bone tissue regeneration are
relatively chemically inert with unreactive species presented at the surface. Therefore, to
attach specific biomolecules, a functional group is often required for the more complex
methodologies. Aminosilane chemistry and plasma polymerisation are commonly used for
this process [26,37–45]. These methodologies can also introduce more control over dosage
and release rate, which is important, as it has been shown, for example, that high concen-
trations of RGD, a commonly used peptide, can be detrimental to cell adhesion [33,46].
Careful consideration when choosing attachment methodology is therefore important.
As there is a wide diversity of methodologies presented in the literature, with speci-
ficity depending on peptide and substrate selection, this review focussed on four broad
attachment methodologies regularly used to allow for comparison, and to summarise the
more general advantages and disadvantages of these methods: adsorption, silanisation,
carbodiimide crosslinking and click chemistry, represented in Figure 1, as well as hydrogel
incorporation, another commonly used peptide delivery method.
 
γ
Figure 1. A diagram representing four common peptide attachment methods: adsorption, silanisation, carbodiimide
crosslinking and click chemistry.
3.1. Adsorption
Most of the existing research in this area has involved passive surface adsorption
of peptides as the chosen delivery method. For this methodology, substrates are simply
incubated in solution of the chosen peptide [37,38,47]. In physical adsorption, the proteins
or peptides are held in place by weak ionic interactions and/or van der Waals forces [26].
Adsorption sometimes relies on the alteration of the originally designed peptides
by the addition of amino acid sequences, with a specific affinity for the chosen carrier
material (e.g., polyglutamate, polyaspartate sequences, non-canonical amino acids such
as γ-carboxyglutamate or phosphoserine, all of which show a specific affinity for calcium
phosphates) [37–39,48]. This could have an effect on the peptide, for example, the additional
amino acids can impact the secondary structure of the peptide, thus interfering with cellular
interactions [38]. However, the extent to which these affinity sequences affect the efficiency
of the signalling peptide are still disputed in the literature [38,45].
Adsorption has been used with many different peptides and substrates, allowing for
improved osteogenic properties both in vitro and in vivo. However, adsorption requires
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certain considerations. While technically simple, this system is plagued with complications
such as: ectopic dispersion, surface dispersal, concentration control and peptide confor-
mation/orientation [26]. The release of the peptide is often not examined in the literature,
however when measured it is high. Saito et al. [43] noted 50% release over 14 days, and
Lin et al. [49] and Li et al. [50] saw 100 and 60% release over 4 days, respectively. With
the concerns over ectopic bone formation and previously mentioned high dose issues, this
high level of release could potentially cause problems in vivo.
3.2. Silanisation
One method which allows for peptide conjugation is aminosilane chemistry or silani-
sation. This is a technique used to generate functional groups at the surface of materials
for the attachment of peptides [45]. Surfaces which contain hydroxyl groups, such as
glass, are functionalised with alkoxysilanes, leaving a surface which can then be further
functionalised through polymerisation. While not specifically used to attach peptides to
substrates, a large section of the literature has used this method to functionalise surfaces to
allow for peptide conjugation.
During silanisation, the surface is first cleaned and oxidised using an oxidising agent,
such as piranha solution, to leave the hydroxyl groups required [51]. The activated surfaces
are then placed into an alkoxysilane, either solution or atmosphere, where silanisation
occurs, attaching the siloxane to the surface. The head of the siloxane is reactive, which
allows for covalent attachment of the desired functional group.
The technique has been shown to be nontoxic and repeatable in many in vitro and
in vivo investigations, and has therefore been used to allow for the binding of osteogenic
peptides with high success [26,44,45,52,53].
However, there are disadvantages associated with this functionalisation technique
when compared to others. Firstly, silanisation is a method of surface modification, and a fur-
ther step is required to bind the peptides to the surface, which can vary in difficulty [54–56].
As silanes require an oxidised surface, this can be a limiting factor in material selection [57].
Silanisation processing conditions vary, with some requiring 120 ◦C heat for 4 h [45], which
could be problematic on a substrate containing organic components. There are also reports
which indicate the silane layer, generated in the grafting of amino groups, can significantly
diminish the original osteoconductive properties of the biomaterial, and also negatively
affect the pH of in vitro cultures [58,59].
3.3. Carbodiimide Crosslinking
If a surface has a suitable reactive species, either through substrate choice or surface
modification, chemical conjugation is possible. One method of chemical conjugation is us-
ing carbodiimide crosslinker chemistry, which allows for crosslinking with an amide bond.
Other similar functional groups can be used for a similar bond, but carbodiimides have
advantages as they allow for zero-length crosslinking, preventing the need for additional
atoms which can negatively affect cellular interaction, have mild aqueous reaction condi-
tions, which include ambient temperatures and pressures, and produce relatively harmless
by-products which are easily removed through washing steps [60]. Various in vitro and
in vivo studies have shown that carbodiimide generated crosslinks are not cytotoxic and
are resistant to enzymatic digestion, and demonstrated success covalently binding col-
lagen to substrates [61–63]. This makes them suitable candidates for the conjugation of
osteogenic peptides.
There are three main carbodiimides used, dicyclohexylcarbodiimide (DCC) and N,N’-
diisopropylcarbodiimide (DIC) and 3-(dimethylaminopropyl)-3-ethylcarbodiimide (EDC).
Both DCC and DIC are allergens and insoluble in water; EDC carries neither of these
disadvantages is therefore the most commonly used [64]. EDC reacts with carboxyl groups
to form an active O-acylisourea intermediate, which is then displaced by nucleophilic
attack from the primary amino groups of peptides, forming an amide bond and isourea
as a by-product. However, carbodiimide crosslinking can have issues. O-acylisourea can
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undergo hydrolysis, recovering the system to the unreacted state, which is particularly
problematic due to the high amount of water present in the aqueous reaction conditions [65].
With a large excess of EDC in the reaction system, there can sometimes be the formation of
N-acylisourea as a side reaction [66].
Succinimidyl esters are often employed to help alleviate these issues. The use of
N-hydroxysulfosuccinimide (NHS) produces a less hydrolysis sensitive intermediary com-
pound allowing for more efficient peptide conjugation [65]. The addition of NHS also
prevents the formation of N-acylisourea since the succinimidyl ester cannot undergo dis-
placement. The addition of NHS causes the potential formation of a different by-product,
sulfo-β-alanine, which is also reported to be easily removed by washing steps and has a
relatively low toxicity [66].
Carbodiimides also have potential drawbacks, however. One negative complication of
EDC peptide conjugation is that certain amino acids can potentially react with the EDC in
side-reactions (e.g., histidine, tyrosine and cysteine) which reduces conjugation efficiency,
however these issues can be combatted through different specific means, dependent on the
peptide chosen [66]. This makes them a promising choice for peptide conjugation.
3.4. Click Chemistry
Click chemistry is a term used to describe a range of chemical reactions for molecule
conjugation. Click reactions are defined by certain properties, all of which make them
advantageous in surface conjugation [67–69]. They have a high yield, producing low
levels of ideally inoffensive by-products. They take place in ambient conditions, and are
exothermic, with a thermodynamic driving force toward a single reaction product. These
benefits have therefore seen them used for the conjugation of peptides to substrates, with
some use in the osteogenic field [70–75].
In the most common click reaction, the copper-catalyzed azide-alkyne substitution
(CuAAC), compounds with azide and alkyne end groups are reacted in the presence of
a Cu(I) catalyst, with a 1,3-dipolar cycloaddition forming a 1,2,3-triazole bond [68,69,74].
This process has advantages over other conjugation methods as the bonds have stability in
aqueous conditions and suitability for long term storage.
However, click chemistry has problems. The initial reactive species required for the
click reactions mean that both the peptides and the surface may need modification to give
them the specific endgroups to allow for the reactions to take place [70,71]. The reactions
themselves also each have potentially negative considerations. For example, with the
CuAAC, the copper introduced into the system which is difficult to remove and can cause
toxicity in vivo [72]. The use of some azides may also be problematic at larger scales due to
their inherent reactivity and explosivity [73]. Other click reactions are based around thiols,
which are sensitive to oxidisation that leaves them unreactive, and this therefore must be
considered when designing the reaction [74].
3.5. Hydrogel Incorporation
While some articles have peptides conjugated to the surface of hydrogels, others
have instead incorporated the peptide within their hydrogel and seen generally positive
results, both in vitro and in vivo [29,76–79]. Hydrogels have high cytocompatibility and a
low inflammatory profile, and their mechanical properties can be tailored during produc-
tion [78]. Despite these benefits, there are properties of hydrogels which may make them
unsuitable for osteogenic use. The mechanical strength of hydrogels is generally lower
than that of both bone and other bone graft materials, which may limit their clinical use,
and the degradation rate of hydrogels must be well considered during design, in order to
ensure a sustained release of the incorporated peptide and thereby avoid potential ectopic
effects [80].
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4. Peptide Selection
Alongside attachment methodology, the selection of peptides provides a method to
control the efficacy of an alloplastic bone graft, with choice and specific sequence both
playing a role in the overall success. Many different peptide groupings and sequences
have been tested in literature. A few select peptide groupings were selected and discussed
further based upon their significant impact in the research and clinical sectors: RGD,
PHSRN, FHRRIKA, KRSR, GFOGER, P15 and the BMP mimetic peptides. In order to
compare these peptides, the studies are summarized through the peptide grouping, specific
amino acid sequence, attachment methodology, substrate material, and if there was or not
a significant increase or decrease to cell attachment, spreading, differentiation and matrix
mineralisation of a bone specific cell type in vitro, and any significant differences shown
in vivo.
4.1. RGD Peptide
With approximately 90 wt.% of organic bone matter consisting of collagen type I,
a large selection of peptides have been isolated from this protein and investigated for
specific bioactivity (examples include RGD, GFOGER, DGEA, BCSPTM-1 and P15) [33,34].
The most comprehensively researched peptide is RGD (Arg-Gly-Asp), first discovered by
Pierschbacher et al. in 1984 [81]. This sequence is part of a ligand found in many bone
matrix proteins such as fibronectin (FN), vitronectin (VN) and collagen [82]. Attachment to
RGD and many other similar adhesion peptides is mediated through cell surface receptors,
found in the integrin superfamily, recognition and interaction. However, there is a redun-
dancy in integrin affinity for adhesion peptides which leads to many cells possessing the
same integrins, and as a result may cause non-specific cell attachment to certain common
adhesion peptides [83].
There are many publications regarding the development of bone-related materials
coated with RGD based peptides, shown in Table 1, commonly using adsorption to attach
them to substrates, with studies consistently reporting improved osteogenic cell attachment
and spreading in vitro [29,54,76].
Table 1. The use of RGD peptides to enhance bone regeneration. ↑ = increase, ↓ = decrease, ≈ = no change, - = not reported.
Abbreviations: ABM = anorganic bone matrix, BMSC = bone mesenchymal stem cells, HO = human osteoblasts, PET =
polyethylene terephthalate, PS = polystyrene, PLGA = poly(lactic-co-glycolic acid), RCO = rat calvaria osteoblast-like,


























GPenGRGDSPCA Adsorption HA HMSC ↑ ↓ - - - [37]
RGD Adsorption Titanium SAOS-2 ↑ ↑ ↑ - - [47]
GPenGRGDSPCA Adsorption HA HMSC ↑ ↓ - - - [38]
RGD Adsorption PS RCO ↑ - - - - [84]
GRGDSPK Adsorption PS RCO ↑ - - - - [84]
MAP(RGDSP) Adsorption PS RCO ↑ - - - - [84]




↑ ↑ - - - [40]
RGDS Adsorption Glass RCO ↑ - - - - [85]
YRGDSPC Silanisation HA HO ↑ - - - - [39]
CGGRGDS Silanisation Titanium RBMSC ↑ ↑ - - - [56]
RGD Silanisation Titanium SAOS2 ↑ ↑ - ↑ - [86]
CGGNGEPRGDTYRAY Silanisation Quartz RCO ↑ ↑ - ↑ - [55]
RGD Silanisation HA MG63 ↑ ↑ - - ↑ [52]



























GGRGDS Silanisation Glass HMSC ↑ ↑ ≈ - - [54]
RGDS Silanisation Glass RCO ≈ - - - - [87]
RGDS Carbodiimide Silk HO ↑ ↑ - - - [88]




↑ - - - - [90]
GRDSPC Carbodiimide PET HMSC ↑ ↑ - ↑ - [91]
K16(GRGDSPC) +
BMSCs
Carbodiimide PLGA BMSC - - ≈ ≈ ≈ [92]
K16(GRGDSPC)
+ TGF-β + BMSCs
Carbodiimide PLGA BMSC - - ↑ ↑ ↑ [92]








Hydrogel RBMSC ↑ - ↑ ↑ - [70]
GRGDS Hydrogel PEG RBMSC ↑ ↑ - - - [76]





48C2 MG63 ↑ - - - - [79]
GRGDS
+ BMP-2
Hydrogel PEG HMSC ↑ ↑ ↑ ↑ ≈ [78]
RGD does not always increase cellular adhesion and spreading, however. A longer
chain RGD (GPenGRGDSPCA) was adsorbed to hydroxyapatite and examined in studies
from Hennessy et al. [37] and Sawyer et al. [38]. While human MSCs (HMSCs) were able
to attach to the material, cell spreading was poor. It was theorised that while RGD is
useful as it provides a cellular binding site, on a material such as hydroxyapatite, which
already absorbs proteins that themselves provide a stronger binding site (e.g., FN, VN), the
RGD may competitively bind cells and therefore lead to an overall weaker attachment [37].
Sawyer et al. [38] hypothesised that the lack of effect may be due to the adsorption of
the peptide itself, and recommended a covalent attachment method—however noted that
this may alter useful surface properties. It is therefore important to consider the substrate
alongside the desired peptide in order to optimise the osteogenic properties for use in bone
graft applications.
RGD has been used in vivo for bone regeneration. Zhang et al. [52] attached RGD
to hydroxyapatite through silanisation and demonstrated improved bone healing when
implanted into the femoral condyles of rabbits, although little discussion as to why RGD
had this effect is included. A recent in vivo study performed by Scholz et al. in 2013 [94]
comparing spinal fusion in sheep treated with either cyclic RGD or rhBMP-2, indicating a
similar effectiveness in promoting bone regeneration, with the three-dimensional structure
of cyclic RGD thought beneficial through increased receptor affinity. Pan et al. [92], however,
found a longer chain version of RGD had limited results in vivo, with rabbit femoral defects
only healing when transforming growth factor β (TGF-β) was included into their scaffold.
These limited effects have also been highlighted in several studies which examined RGD
peptide efficacy further than attachment and spreading.
While further cellular effects of RGD have been studied, with increased osteogenic
differentiation and matrix mineralisation reported [47,55,70,89], there is a lack of consensus
on these within the literature, and Pan et al.’s observation that additional inclusions are
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required to allow for the RGD improvement is a common occurrence. Bilem et al. [54]
and Dee et al. [87] both attached an RGD peptide to glass coverslips through silanisation.
Dee et al. saw no effect on osteoblast adhesion and hypothesised that, while RGD allows
for integrin binding, this alone may not be good enough to increase attachment and a
more complex methodology would be more suitable. Bilem et al. [54] examined human
MSC attachment to the surface, and witnessed attachment and spreading. They did not,
however, encounter osteogenic differentiation, though the cells’ stemness was removed.
They hypothesised that while RGD was useful for cellular attachment, osteogenic markers
or factors were required to fully induce osteoblastic differentiation. This ties in to work from
Moore et al. [71] who examined RGD attached to SAMs through click chemistry, and found
HMSCs did not differentiate. Moore et al. theorised that this was due to a lack of osteogenic
medium, highlighting that where MSC differentiation had been triggered by RGD in He
et al.’s study [70], osteogenic media was used. The use of osteogenic medium must therefore
be taken into account when assessing the results of in vitro studies with MSCs, with the
other literature also pointing to a positive RGD differentiation effect also including specific
osteogenic supplements in their media [93]. A study by Shekaran et al. [78] demonstrated
increased differentiation and proliferation from an RGD peptide, however in their case
this was part of a hydrogel which contained BMP-2, another osteogenic inclusion. These
studies demonstrate that whilst RGD is usually capable of increasing cellular adhesion,
RGD alone does not cause increased osteogenesis, and there are more factors to consider
when designing a peptide-enhanced bone graft material.
4.2. PHSRN Peptide
PHSRN (Pro-His-Ser-Arg-Asn) is a peptide derived from fibronectin, and though
it is not effective alone, it has been demonstrated to have a synergistic effect with RGD
to enhance cellular activity through allowing for α5β1 integrin binding [47,93]. There is
a range of the literature covering the use of these peptides together, shown in Table 2,
however with mixed results.
Table 2. The use of PHSRN peptides to enhance bone regeneration. ↑ = increase, ↓ = decrease, ≈ = no change,


























PHSRN Adsorption Titanium SAOS-2 ≈ ≈ ≈ - - [47]
CGGPHRSN Silanisation Titanium RBMSC ↑ ↑ - - - [56]
RGD + PHSRN Adsorption Titanium SAOS-2 ↑ ↑ ≈ - - [47]
RGD + PHSRN Adsorption Titanium SAOS-2 ↑ ↑ ≈ - - [47]
GRGD + G13 +
PHSRN
Adsorption PS BMSC ↑ - ↑ - - [95]
CGGRDGS +
CGGPHSRN
Silanisation Titanium RBMSC ↑ ≈ - - - [56]





↑ - - - - [96]
GRGD + G13 +
PHSRN
Hydrogel PEG RCO ↑ ↑ ↑ ↓ - [29]
In a study by Paredes et al. [56], RGD and PHSRN did not improve rat bone MSC
spreading on titanium surfaces, with RGD alone performing better in their tests. They
concluded this was due to RGD and PHSRN working similarly through providing sites for
α5β1-mediated adhesion and instructing cells to adhere, therefore making a combination
redundant. This contradicts work from others who have combined RGD and PHSRN
in more complex ways and demonstrated synergistic effects. Mas-Moruno et al. [47]
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compared RGD and PHSRN alone to a mixture of the two peptides immobilised to the
surface of titanium. Alongside this, they also created a dimeric platform containing both
peptides together, with a spacing between the peptides mimicking that found in natural
fibronectin. The mixture of peptides did not increase SAOS-2 (an osteoblast-like cell line)
cellular spreading and proliferation compared to RGD alone, however the dimeric platform
did. This data is shown in Figure 2, and indicates that using peptides in a conformation
more similar to nature is highly beneficial. Neither the mixture nor platform significantly
increased osteogenic differentiation, however, whereas RGD alone did, although this
was linked to the cells exposed to combination peptides having higher proliferation and
therefore reduced phenotype expression.
A combination of RGD and PHSRN which more closely mimics their natural confir-
mation was used by Benoit et al. [29], with a longer chain RGD allowing for larger spacings
between the peptides. Attachment, spreading and cell differentiation were improved
compared to RGD alone. Matrix mineralisation decreased, thought to be due to the peptide
being recognised by the cells as extracellular matrix (ECM), and therefore down-regulating
ECM production. The improved attachment, spreading and differentiation were thought
to be not only due to the synergistic effect of RGD and PHSRN, but also the extended RGD
chain mimicking the spacing between RGD and PHSRN found in nature, again highlight-
ing the benefits to efficacy that can be delivered through a more considered biomimetic
approach. The synergistic effect of the inclusion of PHSRN with RGD improved results,
particularly when the peptides were used in a more natural configuration. However, over-
all, the the literature highlights a lack of potential for osteogenic effects from these peptides,
and as such, other peptides have been studied.
4.3. FHRRIKA and KRSR Peptides
Osteoblast cell attachment is not only mediated through integrin binding, but also by
the interaction of transmembrane heparan sulphate proteoglycans with heparin binding
sequences found within many different proteins associated with bone tissue. These types
of additional interactions are also believed to significantly impact osteoblast attachment
behaviour, as heparan sulphate has been detected immunohistochemically on the mem-
branes of osteogenic cells attached to formed bone matrix [87,97]. Based on their promising
publication history and complementary action, FHRRIKA and KRSR have potential for
future clinical impact, and studies using these peptides are shown in Table 3.
 




Figure 2. Spreading of Saos-2 cells on biofunctionalized surfaces after 4 h of incubation. (A) Ctrol,
(B) RGD, (C) PHSRN, (D) MIX, and (E) Platform. Images were acquired by fluorescence microscopy
and show only staining of actin filaments with phalloidin-rhodamine. Scale bars: 200 µm. Repro-
duced with permission from [47].
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Table 3. The use of FHRIKKA and KRSR peptides to enhance bone regeneration. ↑ = increase, ↓ = decrease, ≈ = no change,


























(G7 or E7)FHRRIKA Adsorption HA HMSC ↑ ↑ - - - [38]
CGGFHRRIKA Silanisation Quartz RCO ↑ ↑ - ≈ - [55]
CGGFHRRIKA Silanisation Titanium RBMSC ↑ ↑ - - - [56]
FHRRIKA Carbodiimide POSS-PCU BMSC ↑ ↑ ↑ - - [98]
GFHRRIKA Carbodiimide PET HMSC ↑ ↑ - ↑ - [91]
(G7 or E7)KRSR Adsorption HA HMSC ↑ ↑ - - - [38]
KRSR Adsorption PS RCO ↑ - - - - [84]
KRSR Adsorption PS RCO ↑ - - - - [84]
MAP(KRSR) Adsorption PS RCO ↑ - - - - [84]
KRSR Adsorption Glass RCO ↑ - - - - [85]
KRSRGGG Silanisation Glass RCO ↑ - - - - [87]
KRSRGYC Silanisation Titanium HO ↑ - - - - [41]
KRSR Silanisation Titanium SAOS2 ↑ ↑ - ↑ - [86]
KRSR Carbodiimide Silk HO ↑ ↑ - - - [88]
KRSR Carbodiimide POSS-PCU BMSC ↑ ↑ ≈ - - [98]
FHRIKKA + KRSR Carbodiimide POSS-PCU BMSC ↑ ↑ ↑ - - [98]
First reported in 1999 by Rezania and Healy [55], FHRRIKA (Phe-His-Arg-Arg-Ile-Lys-
Ala) is a peptide isolated from the heparin binding domain of BSP (Figure 3). This peptide
is reported to significantly enhance cell proliferation, spreading, and in some cases, matrix
mineralisation [38,98–100]. Rezania and Healy functionalised quartz discs with FHRRIKA
through silanisation and showed that FHRRIKA modified surfaces significantly enhanced
cell spreading, however saw little effect on mineralisation [55]. FHRRIKA enhanced cell
attachment and spreading were in a paper published by Paredes et al. [56], on titanium






Figure 3. The chemical structure of FHRRIKA (left) and KRSR (right) peptides.
KRSR (Lys-Arg-Ser-Arg), is also a heparin binding peptide, present in bone sialopro-
tein, FN, VN, osteopontin and thrombospondin (Figure 3) [100]. It was first reported by Dee
et al. [87] in 1998, where it was shown to selectively enhance osteogenic cell adhesion on
borosilicate glass functionalised using aminosilane chemistry. Dee et al. also hypothesised
KRSR may be subject to binding through αvβ5 integrin receptors, alongside the heparin
binding sequence, further increasing attachment. Osteoblast cells are known to express
this integrin, and therefore this peptide has high potential in the osteogenic field, which
has been explored in the literature.
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The selective osteoblast attachment has also been demonstrated by Hasenbein et al. [85]
though the micro patterning of KRSR on borosilicate glass using elastomer stamps. This
selective attachment gives KRSR an advantage over non-specific peptides, as it allows
for the direct targeting of bone cells. Like RGD, KRSR has demonstrated consistent suc-
cess in allowing for attachment and spreading, with various attachment methodologies
and substrates [38,41,79,84,88,101]. However, Dettin et al. [84] found that RGD increased
osteoblast attachment to a higher degree than KRSR, using different attachment methodolo-
gies and substrates, though did not explain this difference. Anderson et al. [102] witnessed
a similar effect in a study using HMSC cells, and this potential limitation of KRSR requires
further investigation.
In a report published by Gentile et al. [98] FHRRIKA and KRSR peptides were attached
to polyhedral oligomeric silsesquioxane nano particles, functionalised through plasma
polymerisation of acrylic acid and subsequent carboxyl activation via EDC/NHS. In this
work the peptides did increase the attachment of MSC cells, and FHRRIKA peptides
resulted in a significant increase in alkaline phosphatase (ALP) production, indicating the
differentiation of the cells, though KRSR did not increase differentiation more than plasma
treatment alone. This lack of consistency present in the literature is an area where more
study is required.
Whilst both FHRRIKA and KRSR have demonstrated success in enhancing the os-
teogenic properties of materials, study has been relatively limited and further work is
required to fully elucidate their cellular effects across the different cells that contribute to
bone regeneration, and their osteogenic capacity in vivo before widespread use [103].
4.4. GFOGER Peptide
GFOGER (Gly-Phe-Hyp-Gly-Glu-Arg) is another peptide derived from collagen,
specifically from the α1 chain of collagen-1. When manufactured, Gly-Pro-Pro ends are
often included, which allow the peptide to take up a collagen-mimicking triple helical
structure, which is essential for α2β1 integrin binding, part of the peptide’s mechanism of
action. This binding enhances development and expression of an osteoblastic phenotype
and is therefore important for differentiation, and it is also has been demonstrated to
improve matrix mineralisation [104]. GFOGER has an advantage in osteogenic properties
over native collagen, as other competitive binding sites are found on native collagen, but
not present on the GFOGER sequence, which allows for a more specific effect [105]. This
specific osteogenic effect allows for advantages in osteogenic applications over entirely
adhesive peptides, such as RGD [78], and several studies have investigated its use in these
applications.
GFOGER has been used successfully to increase cellular attachment, osteogenic dif-
ferentiation and matrix mineralization of stem cells, and has also demonstrated success
in vivo in bone healing studies [78,93,104–106]. These studies have involved a variety of
attachment methodologies and substrates, shown in Table 4.
One such study was performed by Shekaran et al. [78], who demonstrated that
polyethylene glycol-BMP-2 hydrogels modified with surface GFOGER could increase
cell spreading and osteogenic differentiation in BMSCs, in comparison to an RGD modi-
fication. When studied in vivo, they demonstrated that GFOGER could promote healing
even without the inclusion of the BMP-2 component of the hydrogel, shown in Figure 4.
These results highlight the potential of GFOGER for use in osteogenic applications.
Hennessy et al. [37] adsorbed GFOGER to the surface of hydroxyapatite disks, how-
ever found GFOGER was unable to increase cell attachment and decreased cell spreading,
and were unable to explain this issue. Wojtowicz et al. [105] commented on this and claimed
this may be due to a difference in peptide sequencing, as they showed positive results
in a similar study. This demonstrates the importance of peptide selection, even within
one peptide grouping, with a peptide which can more closely mimic the natural protein
favourable. The nature-mimicking conformation of GFOGER is therefore a promising
peptide for use in this field.
J. Funct. Biomater. 2021, 12, 22 13 of 24
Table 4. The use of GFOGER peptides to enhance bone regeneration. ↑ = increase, ↓ = decrease, ≈ = no change, - = not




























Adsorption HA HMSC ≈ ↓ - - - [37]
GGYGGGPC(GPP)5
GFOGER
Adsorption PCL HMSC ↑ ↑ ↑ - - [106]
GGYGGGPC(GPP)5
GFOGER(GPP)5GPC
Adsorption Titanium BMSC ↑ ↑ ↑ ↑ ↑ [104]
GGYGGGPC(GPP)5
GFOGER(GPP)5GPC
Adsorption PCL BMSC - - - - ↑ [105]
GGYGGGPC(GPP)5
GFOGER(GPP)5GPC
Carbodiimide Hydrogel BMSC ↑ ↑ ↑ - - [93]
GGYGGGPC(GPP)5
GFOGER(GPP)5GPC













Figure 4. GFOGER-functionalized PEG hydrogels with low dose BMP-2 bridge radial segmental defects without altering
ulnar structure. (A) Radiographic images, white arrows indicate space between ulna and radius which is not present in the
high BMP-2 dose image, scale bar 2 mm. (B) 3D µCT reconstructions of (i) radius in sagittal view (left) with mineral density
mapping (right), and (ii) radius and ulna in transverse view. Yellow arrowheads indicate boundary between the ulna and
radius prior to implantation, red arrowheads indicate the position of the ulna closest to the radius at 8 weeks, scale bar 1
mm. (C) µCT measures of bone formation, n = 6–7. (D) Scoring of defect bridging at 8 weeks, n = 6–7. (E) Sections stained
with Safranin-O/Fast Green at the center of defect, scale bar 50 µm; b—bone, bm—bone marrow. (F) (i) Representative
FMT images and FMT quantification of % implanted dose retained in radial defect space over time in vivo for (ii) high
dose BMP-2 labeled with Vivotag 800 and (iii) GFOGER peptide labeled with Vivotag 680, n = 6. * p < 0.05, ** p < 0.01,
*** p < 0.001 compared to defect receiving no hydrogel implant, # p < 0.05 compared to GFOGER hydrogel. Reproduced
with permission from [78].
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4.5. P15 Peptide
P15 is again a peptide based upon a sequence of collagen (Gly-Thr-Pro-Gly-Pro-Gln-
Gly-Ile-Ala-Gly-Gln-Arg-Gly-Val-Val) (Figure 5). It is a high affinity ligand found in the α1
helix of collagen type I, 766–780 residues, which interacts with a specific collagen binding
cell surface integrin (α2β1) [37]. First reported by Bhatnagar et al. in 1997 [107], the P15
peptide has been shown in vitro and in vivo to enhance osteogenic cell attachment and
proliferation, and in some more recent publications has also been shown to stimulate MSC
differentiation [108,109]. When P15 is present at the surface of a material it functions as a
substitute for collagen type I. The binding of cell surface integrins (α2β1) to P15 leads to the
production of growth factors and cytokines, which in turn stimulate matrix production and
mineralisation [110]. As the integrin α2β1 is known to be collagen specific, it is believed
that this interaction would not compete with other cell surface integrins for FN (αIIbβ3 or
α5β1) or VN (αvβ3), proteins found in blood [37]. P15 interaction is RGD independent,
whereas VN and FN both bind integrins through RGD mechanisms [37].
α β α β α β
 
  ≈
     
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Figure 5. The chemical structure of P15 peptide.
Of the collagen-based peptides mentioned in Section 4.1, P15 is the only sequence
currently FDA approved for use in either periodontal defects, PepGen P-15™ (Dentsply©)
or cervical disc reconstruction, i-Factor™ (Cerapedics©). P15 has also received significant
attention as it interacts with cells through a specific integrin, and therefore does not compete
with other protein interactions [37]. This sequence is supported by a large body of in vitro
studies and clinical trials, and carries specific commercial value [11,12,18,110–116]. As P15
is currently available on the market, for dental (PepGen® (Dentsply©) and orthopaedic
(i-Factor® (Cerapedics©)) applications, there is a large body of published literature sur-
rounding its successful use, with some shown in Table 5.
























GTPGPQGIAGQRGVV Adsorption HA HMSC ↑ ↑ ↑ ↑ ↑ [37]
GTPGPQGIAGQRGVV Adsorption HA HMSC ↑ ↑ ↑ ↑ - [117]
GTPGPQGIAGQRGVV Silanisation Titanium C3H10T1 ↑ ↑ ↑ ↑ - [53]
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Studies have investigated P15 adsorbed to bovine bone [107,108,114]. Bhatnagar
et al. [108] showed that P15 stimulated matrix mineralisation and cell differentiation, but
also alluded to problems surrounding peptide dissolution and concentration. Interest-
ingly Bhatnagar et al. also showed that like KRSR, P15 can inhibit fibroblast adhesion,
which increases its relevance to the osteogenic field [107]. Nguyen et al. [114] showed
the beneficial effects of P15 persisted even when coated bovine bone was immobilised
in an inert hydrogel carrier, and similar effects have been demonstrated with titanium
surfaces modified through silanisation by Liu et al. [53]. These results demonstrate the
high potential of P15 in the field, with the bone cell specificity of KRSR but with a strong
backing of data evidencing its efficacy in in vitro and in vivo studies.
There have been several studies demonstrating the efficacy of P15 in vivo. In animals,
ANKYLOS® (Dentsply©) and i-Factor® (Cerapedics©) significantly enhanced bone regen-
eration in alveolar bone in dogs and the tibia of osteoporotic dogs, respectively, in studies
from Pedersen et al. [110] and Schmitt et al. [118]. However, Pedersen et al. also indicated
that, in normal rats, bone regeneration was not accelerated when treated using i-Factor®.
This is a result that is important to note, whilst bearing in mind the major clinical challenge
of orthobiologics is to provide healing in compromised patients.
Human studies have also been performed in different indications. As part of a large
multi-centre trial, Yukna et al. [111] published the six month findings of human patients
with periodontal osseous defects treated with a P15—bovine bone graft material. The study
indicated that bone regeneration was enhanced in the presence of P15, which potentially
also had a knock-on effect in stimulating enhanced regeneration of the periodontal ligament.
Anterior lumbar interbody fusion using P15—bovine bone (i-Factor® (Cerapedics©)) was
investigated in 110 human patients in a published study by Mobbs et al. in 2014 [112]. In
this study, it was concluded that the P15 substitute demonstrated similar clinical outcomes
to patients treated with either autograft or Infuse® (Medtronic©). However, a clinical
evaluation published by Kasaj et al. [119] indicated no significant differences between
groups treated by traditional means and those treated with P15—bovine bone in a hydrogel
carrier. These results may be related to peptide dispersion, as here P15 was adsorbed to the
surface of the xenograft and not covalently anchored.
There are numerous other clinical studies involving bone regeneration stimulated
through the use of P15, which can be found detailed in a review published by Pountos
et al. [33]. To summarise, bone tissue regeneration augmented with P15 was shown to be
effective in a number of different indications, and has demonstrated the ability to improve
regeneration in a compromised healing model. These results, and the market approval for
existing P15 based products, make it an attractive solution.
4.6. BMP Mimetic Peptides
Peptides derived from BMPs have also seen use in this field, with the literature
generally focused on the BMP-2 mimetic peptide, also known as P24 (Ser-Lys-Ile-Pro-Lys-
Ala-Ser-Ser-Val-Pro-Thr-Gly-Leu-Ser-Ala-Ile-Ser-Thr-Leu-Tyr-Leu-Asp-Asp-Asp), however
with some use of BMP-7 and -9 mimetic peptides. These peptides contain the knuckle
epitope of the protein, and bind to BMP receptors as their mechanism of action, and
are 20+ amino acids in length. BMP mimetic peptides have shown universally positive
results across a variety of attachment methodologies and substrates, shown in Table 6,
with several also demonstrating in vivo efficacy by inducing ectopic bone formation in
rodents [49,120,121].
Although they are effective, BMP-2 and its associated peptide have a short retention
time in the body, reducing their efficiency [49]. For this reason, research has focused on
defining suitable substrates and attachment methodologies to prolong the release of the
BMP-2 mimetic peptide to allow for sustained osteogenesis.
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Table 6. The use of BMP mimetic peptides to enhance bone regeneration. ↑ = increase, ↓ = decrease, ≈ = no change, - = not
reported. Abbreviations: αTCP = α tricalcium phosphate, PAA = poly(acrylamide-co-acrylic acid), PLA = polylactic acid,


























HO ↑ ↑ ↑ ↑ ↑ [50]











HMSC ↑ ↑ ↑ - - [42]
EEEEEEEKIPKASSVPTELSAIS
TLYL
Adsorption PLGA - - - - - ↑ [123]
KIPKASSVPTELSAISTLYL Silanisation Glass HMSC ↑ ↑ ↑ - - [54]
KIPKASSVPTELSAISTLYLDDD Carbodiimide PLGA - - - - - ↑ [120]
KIPKASSVPTELSAISTLYLDDD Carbodiimide PLGA HO ↑ ↑ ↑ ↑ ↑ [49]
KIPKASSVPTELSAISTLYLDDD Carbodiimide Alginate C3H10T ↑ - ↑ ↑ - [121]
KIPKASSVPTELSAISTLYLDDD Carbodiimide Alginate - - - - - ↑ [121]
KIPKASSVPTELSAISTLYLDDD Carbodiimide Alginate - - - - - ↑ [124]
NSVNSKIPKACCVPTELSAI Carbodiimide Alginate - - - - - ↑ [125]













Hydrogel RBMSC ↑ ↑ ↑ ↑ - [127]
Research has investigated both simple and complex methodologies to achieve the
necessary attachment. Niu et al. [42] encapsulated their peptide into chitosan microspheres,
before blending these into a polymer, which slowed the full release of the encapsulated
peptide to approximately 18 weeks. Lin et al. [49] compared adsorption to EDC-NHS
mediated covalent binding of BMP-2 mimetic peptide to a PLGA-(PEG-ASP)n polymer.
In their study, the use of EDC-NHS slowed the release rate drastically, altering the release
from 100% within 4 days to only approximately 70% over 14 days, shown in Figure 6, and
showing ectopic bone formation over 12 weeks in vivo. While Li et al. [50] only adsorbed
BMP-2 mimetic peptide to a bone ceramic, with the surface mineralised through use of
simulated body fluid, they also exhibited a release profile similar to that of Lin et al.’s
covalently bound peptide, with a partial release over 14 days and efficiency in vivo over
12 weeks. They posited that due to the BMP-2 mimetic peptide ending with a repeating
Asp sequence, this gave the peptide a high binding affinity for apatite-based materials,
and therefore would allow the peptide to bond to the scaffold without the need for more
complex methodologies. These studies highlight that consideration of substrate and
binding methodology when designing a peptide-enhanced bone graft material can allow
for greatly improved bioactive properties.
As well as studying RGD, both Moore et al. [71] and He et al. [70] attached BMP-2
mimetic peptide to a substrate using click chemistry and investigated the effect on BMSCs.
As discussed in Section 4.1, Moore et al.’s SAMs saw attachment and differentiation, but
no improved mineralisation, and suggested more specific biological signalling may be
required to upregulate this process. He et al. cultured their hydrogel in osteogenic medium
and saw attachment, differentiation and mineralisation, demonstrating the benefits of
this specific signalling. Moore et al. also studied a combination of RGD and BMP-2, and
found that, even without osteogenic medium, the combination of the peptide allowed
for increased mineralisation, with it hypothesised that RGD increased cellular adhesion
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and therefore enhanced the amount of interaction of cells with the bound BMP-2. This
combination effect is a commonly reported phenomenon and has warranted further study.
 
Figure 6. The profiles of P24 peptide released from PLGA-(PEG-ASP)n scaffold in the absence (a) and
presence (b) of NHS/EDC. Reproduced with permission from [49].
4.7. Combinations of Peptides
As the peptides discussed have different mechanisms of action, they are often used
in combination to increase their effects, shown in Table 7. As studies of RGD have found
diminished effects, the use of RGD in conjunction with other peptides, including FHRRIKA
and BMP-2 mimetic peptides, has been investigated. These methodologies allow for a
more specific, tailored approach where peptides with separate mechanisms can increase
the osteogenic properties, compared to either peptide alone. There is a growing body of
evidence that this more tailored approach is beneficial.
The synergistic effect of RGD and BMP noted by Moore et al. [71] in Section 4.6 has
also been noted in the other literature, with RGD thought to increase adhesion while the
BMP mimetic peptide increases the osteogenesis of MSCs [54]. This effect has been seen
with BMP-2 mimetic peptides by Bilem et al. [54], and Zouani et al. [90] who also saw the
same synergy with RGD and BMP-7 and BMP-9 mimetic peptides.
RGD and KRSR both promote cellular attachment, however through integrins and
proteoglycans, respectively. These binding mechanisms can be used in conjunction to
increase attachment further. Dee et al. [87] examined the attachment of osteoblasts onto
glass surfaces to which peptides had been attached through silanisation. When coated with
RGD alone, cells attached but no more than the control glass. KRSR alone increased the
attachment. When both RGD and KRSR were used attachment was increased further, due
to this dual binding mechanism. Rezania and Healy [55] demonstrated that a longer chain
version of RGD (CGGNGEPRGDTYRAY) stimulated rat osteoblast matrix mineralisation
when attached to quartz through silanisation, while FHRRIKA did not. Interestingly, when
an RGD and FHRRIKA combination was used, this improved mineralisation, with higher
FHRRIKA ratios identified as the most biologically relevant.
A study from Schuler et al. in 2009 [100] investigated rough titanium samples modified
with adsorbed poly-L-lysine-graft-polyethylene glycol doped with either FHRRIKA, KRSR
or RGD. This study concluded that while FHRRIKA or KRSR peptides alone promoted
cell proliferation compared to controls, they did not reach the efficiency of RGD or RGD
and FHRIKKA or KRSR combinations in their ability to upregulate cell proliferation. It is
possible this issue may be resolved through the adjustment of peptide concentrations to
alter potency of the signal. The Sawyer et al. [38] study first discussed in Section 4.1 also
examined combinations of peptides, and concluded that combining RGD with either KRSR
or FHRRIKA adsorbed on the surface of HA did not elicit an enhanced response greater
than that of the peptides used alone, although as previously discussed, they hypothesised
that this may have been due to poor adsorption of the peptides to the surface, and that
chemical attachment methods may have improved their results.
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Finally, Gentile et al. [128] used a layer-by-layer assembly methodology to coat the
surface of PLGA electrospun membranes with a combination of FHRIKKA, KRSR and BMP
mimetic peptides, using the peptide’s different osteogenic properties to use in different
layers. These layers were designed to follow the bone healing process, with KRSR used
in the outer layer to improve cell attachment, BMP-mimetic peptides in the middle to
improve differentiation and a final layer of FHRIKKA to improve mineralisation. This
material demonstrated excellent in vitro results and was successful in preliminary in vivo
study. This novel method highlights the strong potential of combinatory solutions, with
consideration to the natural bone healing process.
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Hydrogel RBMSC ↑ - ↑ ↑ - [70]











Carbodiimide PET HMSC ↑ ↑ - ↑ - [91]
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These studies demonstrate that while all these peptides have their own positive
effects, through combining peptides which have complimentary effects it is possible to
further increase their osteogenic properties. Further work, including in vivo study, of these
combinations is required to examine how these tailored approaches translate.
5. Conclusions
Osteogenic peptides may be utilized to improve the properties of alloplastic bone
grafts, with benefits to quality assurance, predictability, cost-effectiveness, and clinical
outcomes. These benefits make peptides ideal for use in the bone graft market, with
several first-generation products approved and in clinical use. However, these are not yet
entirely synthetic or based on covalently bound molecules, and further work is required
to reach full clinical maturity while avoiding the adverse events associated with classical
orthobiologics. Covalently bound peptides provide the greatest control over dosage,
resulting in reduced risk of ectopic effects and greater product stability. Their synthetic
nature may also contribute to reduced manufacturing costs while—depending upon the
nature of attachment—a medical device classification may be appropriate. In order to
fully impact the market, a new generation of wholly synthetic materials must be able to
demonstrate consistent clinical results and at least parity with the current ‘gold standard’
of autografting in biological performance. The inherent benefits of a synthetic product
over other synthetic graft types, in terms of shelf life, transportation, availability, and a
well-defined regulatory pathway, offer a huge market potential once clinical performance
is proven.
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